We are live on ! Find out more
VVM

Versant Venture Management Portfolio holdings

AUM $141M
1-Year Est. Return 190.82%
This Fund
S&P 500
This Quarter Est. Return
+3.55%
1 Year Est. Return
+190.82%
3 Year Est. Return
+375.7%
5 Year Est. Return
+81.85%
10 Year Est. Return
+4,735.29%
AUM
$48M
AUM Growth
-$356K
Cap. Flow
$0
Cap. Flow %
0%
Top 10 Hldgs %
100%
Holding
7
New
Increased
Reduced
Closed

Top Buys

No buys this quarter

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
CRSP icon
1
CRISPR Therapeutics
CRSP
$4.68B
$22.5M 47.01%
498,558
GRTS
2
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
$9.9M 20.64%
3,561,150
PASG icon
3
Passage Bio
PASG
$14.7M
$4.75M 9.9%
247,988
CBAY
4
DELISTED
Cymabay Therapeutics
CBAY
$4.74M 9.88%
543,753
ADVM
5
DELISTED
Adverum Biotechnologies
ADVM
$3.64M 7.58%
506,823
ALGS icon
6
Aligos Therapeutics
ALGS
$26.3M
$2.03M 4.23%
92,815
UTRS
7
DELISTED
Minerva Surgical, Inc. Common Stock
UTRS
$367K 0.77%
83,685

Similar funds

Versant Venture Management's Q1 2023 Portfolio in Review

As of Q1 2023, Versant Venture Management held 7 positions worth $48M, down 0.74% from $48.3M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Trading was light in Q1 2023: portfolio turnover was 0%. Versant Venture Management opened no new positions and made no exits, leaving the 7-position portfolio largely intact.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Versant Venture Management's ten largest holdings make up 100% of its $48M portfolio in Q1 2023.
  • Versant Venture Management opened 0 new positions and closed 0 in Q1 2023.
  • Versant Venture Management's portfolio value fell 0.74% quarter-over-quarter to $48M.

Based on Versant Venture Management's 13F filing for Q1 2023, filed 11 May 2023.